Cantor Fitzgerald Starts Phathom Pharmaceuticals (PHAT) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall St rises as oil falls heading into US midterm elections
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts PHAT Hot Sheet
Price: $5.82 +1.39%
Rating Summary:
12 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 22 | New: 16
Rating Summary:
12 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 22 | New: 16
Join SI Premium – FREE
Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Phathom Pharmaceuticals (NASDAQ: PHAT) with a Overweight rating and a price target of $23.00.
For an analyst ratings summary and ratings history on Phathom Pharmaceuticals click here. For more ratings news on Phathom Pharmaceuticals click here.
Shares of Phathom Pharmaceuticals closed at $5.62 yesterday.
You May Also Be Interested In
- H.C. Wainwright Assumes Nkarta Inc. (NKTX) at Buy
- Nomura/Instinet Starts Huayu Automotive Systems (600741:CH) at Buy
- BTIG Starts SharkNinja (SN) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
